ZFP82

Summary

ZFP82 (ZFP82 zinc finger protein, HGNC:28682) is a protein-coding gene on chromosome 19q13.12, encoding Zinc finger protein 82 homolog (Q8N141). May be involved in transcriptional regulation.

Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be active in nucleus.

Source: NCBI Gene 284406 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 51 total — 1 pathogenic
• MANE Select transcript: NM_133466

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28682
Approved symbol	ZFP82
Name	ZFP82 zinc finger protein
Location	19q13.12
Locus type	gene with protein product
Status	Approved
Aliases	MGC45380, KIAA1948
Ensembl gene	ENSG00000181007
Ensembl biotype	protein_coding
Entrez	284406

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 5 protein_coding, 1 retained_intron

ENST00000392161, ENST00000445543, ENST00000590993, ENST00000855087, ENST00000855088, ENST00000855089

RefSeq mRNA: 4 — MANE Select: NM_133466 NM_001321917, NM_001321918, NM_001321919, NM_133466

CCDS: CCDS12493

Canonical transcript exons

ENST00000392161 — 5 exons

Exon	Start	End
ENSE00001235663	36388630	36394110
ENSE00002207038	36409781	36409867
ENSE00002292593	36405580	36405672
ENSE00002294689	36418492	36418644
ENSE00002306577	36407887	36408013

Expression profiles

Bgee: expression breadth ubiquitous, 227 present calls, max score 92.51.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.5776 / max 72.2715, expressed in 1488 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
180672	4.1489	1397
180671	1.3443	722
180673	0.0489	10
180674	0.0354	5

Top tissues by expression

244 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	92.51	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	87.85	gold quality
cortical plate	UBERON:0005343	85.85	gold quality
oocyte	CL:0000023	85.76	gold quality
ventricular zone	UBERON:0003053	84.10	gold quality
pigmented layer of retina	UBERON:0001782	83.42	gold quality
ganglionic eminence	UBERON:0004023	82.90	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.92	gold quality
pons	UBERON:0000988	79.80	gold quality
corpus epididymis	UBERON:0004359	79.70	gold quality
dorsal plus ventral thalamus	UBERON:0001897	79.49	silver quality
subthalamic nucleus	UBERON:0001906	79.04	silver quality
kidney epithelium	UBERON:0004819	78.95	silver quality
cauda epididymis	UBERON:0004360	78.85	gold quality
vena cava	UBERON:0004087	78.84	gold quality
caput epididymis	UBERON:0004358	78.71	gold quality
superior vestibular nucleus	UBERON:0007227	78.67	silver quality
ventral tegmental area	UBERON:0002691	78.57	silver quality
lateral nuclear group of thalamus	UBERON:0002736	78.51	gold quality
Brodmann (1909) area 46	UBERON:0006483	78.40	gold quality
lateral globus pallidus	UBERON:0002476	78.26	gold quality
endothelial cell	CL:0000115	78.04	gold quality
medulla oblongata	UBERON:0001896	77.83	silver quality
substantia nigra pars reticulata	UBERON:0001966	77.51	silver quality
sperm	CL:0000019	77.50	gold quality
inferior vagus X ganglion	UBERON:0005363	77.39	silver quality
substantia nigra pars compacta	UBERON:0001965	77.08	silver quality
pericardium	UBERON:0002407	77.01	silver quality
superior surface of tongue	UBERON:0007371	76.89	silver quality
body of tongue	UBERON:0011876	76.66	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	4.86

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

105 targeting ZFP82, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-1229-3P	99.97	66.49	906
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-552-5P	99.93	68.56	1583
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-652-5P	99.91	67.49	505
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-659-3P	99.85	70.69	1620
HSA-MIR-4495	99.82	72.08	3080
HSA-MIR-4307	99.82	70.45	3374
HSA-MIR-6844	99.82	70.69	2423
HSA-MIR-6515-3P	99.82	68.19	1933
HSA-MIR-320A-3P	99.77	69.73	2107
HSA-MIR-320B	99.77	69.73	2107
HSA-MIR-320C	99.77	69.73	2107
HSA-MIR-320D	99.77	69.73	2107

Literature-anchored findings (GeneRIF, showing 6)

• ZNF545 acts as a functional tumour suppressor in gastric cancer by inhibiting rRNA transcription. (PMID:22580414)
• ZNF545 inhibits breast tumor cell proliferation through inducing apoptosis and is disrupted by promoter methylation in breast cancer. (PMID:25360542)
• These findings indicated that the methylated CpG sites of the ZNF545 promoter could be used for the clinical prediction of the prognosis of gastric cancer (PMID:25714013)
• the results suggested that ZNF545 functions as a tumor suppressor in colorectal cancer and is frequently inactivated by promoter methylation. (PMID:28677721)
• ZFP82 is a tumor suppressor and is disrupted by promoter CpG methylation during esophageal carcinogenesis. (PMID:30211622)
• ZNF545 protein promoted the apoptosis of myeloma cells. (PMID:31165610)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Zfp82	ENSMUSG00000098022
rattus_norvegicus	Zfp82	ENSRNOG00000052023

Paralogs (176): ZNF195 (ENSG00000005801), ZNF112 (ENSG00000062370), ZNF275 (ENSG00000063587), ZNF37A (ENSG00000075407), ZNF510 (ENSG00000081386), ZNF506 (ENSG00000081665), ZNF268 (ENSG00000090612), MZF1 (ENSG00000099326), ZNF629 (ENSG00000102870), ZNF175 (ENSG00000105497), ZNF85 (ENSG00000105750), ZFP30 (ENSG00000120784), ZNF45 (ENSG00000124459), ZNF391 (ENSG00000124613), ZNF436 (ENSG00000125945), ZNF484 (ENSG00000127081), ZNF835 (ENSG00000127903), ZNF780B (ENSG00000128000), ZSCAN10 (ENSG00000130182), ZNF317 (ENSG00000130803), ZNF331 (ENSG00000130844), ZNF227 (ENSG00000131115), ZNF141 (ENSG00000131127), ZNF132 (ENSG00000131849), ZNF189 (ENSG00000136870), ZIM3 (ENSG00000141946), ZFP14 (ENSG00000142065), ZNF514 (ENSG00000144026), ZNF300 (ENSG00000145908), RBAK (ENSG00000146587), ZNF157 (ENSG00000147117), ZNF182 (ENSG00000147118), ZNF41 (ENSG00000147124), ZNF7 (ENSG00000147789), ZNF117 (ENSG00000152926), ZNF221 (ENSG00000159905), ZNF235 (ENSG00000159917), ZNF714 (ENSG00000160352), ZNF577 (ENSG00000161551), ZNF12 (ENSG00000164631)

Protein

Protein identifiers

Zinc finger protein 82 homolog — Q8N141 (reviewed: Q8N141)

Alternative names: Zinc finger protein 545

All UniProt accessions (3): D3Y299, Q8N141, K7ERD5

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation.

Subcellular location. Nucleus.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

RefSeq proteins (4): NP_001308846, NP_001308847, NP_001308848, NP_597723* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily

Pfam: PF00096, PF01352

UniProt features (19 total): zinc finger region 13, cross-link 2, sequence conflict 2, chain 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N141-F1	69.74	0.03

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 126, 142

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 89 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_MCMV_INFECTION_UP, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, GCCNNNWTAAR_UNKNOWN, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, MIKKELSEN_ES_ICP_WITH_H3K4ME3, MIKKELSEN_NPC_ICP_WITH_H3K4ME3, KRIEG_HYPOXIA_NOT_VIA_KDM3A, GSE14699_NAIVE_VS_DELETIONAL_TOLERANCE_CD8_TCELL_UP, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, OVOL3_TARGET_GENES, MIR651_3P, MIR4262, GSE10239_NAIVE_VS_MEMORY_CD8_TCELL_UP, GSE10239_NAIVE_VS_KLRG1INT_EFF_CD8_TCELL_UP

GO Biological Process (2): regulation of transcription by RNA polymerase II (GO:0006357), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (5): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), zinc ion binding (GO:0008270), DNA binding (GO:0003677), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
transition metal ion binding	1
nucleic acid binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

352 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZFP82	DDX31	Q9H8H2	419
ZFP82	PARP6	Q2NL67	347
ZFP82	ZPR1	O75312	330
ZFP82	Q6GMV1	Q6GMV1	330
ZFP82	C12orf42	Q96LP6	315
ZFP82	DNAJC15	Q9Y5T4	309
ZFP82	GPR149	Q86SP6	304
ZFP82	FIBCD1	Q8N539	295
ZFP82	TWSG1	Q9GZX9	275
ZFP82	BRINP1	O60477	272
ZFP82	LINGO2	Q7L985	267
ZFP82	HECW1	Q76N89	259
ZFP82	PCDH10	Q9P2E7	250
ZFP82	PCDH17	O14917	249
ZFP82	AJAP1	Q9UKB5	248

IntAct

5 interactions, top by confidence:

A	B	Type	Score
ZFP82	ARIH1	psi-mi:“MI:0915”(physical association)	0.400
CBX5	ZNF568	psi-mi:“MI:0914”(association)	0.350
CTNNB1	ARVCF	psi-mi:“MI:0914”(association)	0.350
CTNNB1	NR3C1	psi-mi:“MI:0914”(association)	0.350

BioGRID (12): ZFP82 (Affinity Capture-MS), ZFP82 (Affinity Capture-MS), ZFP82 (Proximity Label-MS), ZFP82 (Proximity Label-MS), ZFP82 (Proximity Label-MS), ARIH1 (Affinity Capture-MS), ZFP82 (Affinity Capture-MS), ZFP82 (Affinity Capture-MS), ZFP82 (Proximity Label-MS), ZFP82 (Proximity Label-MS), ZFP82 (Affinity Capture-MS), ZFP82 (Affinity Capture-MS)

ESM2 similar proteins: A0JNB1, A6QLU5, O75123, O75820, P10076, P10755, P16374, P17031, P17097, P17141, P51814, Q02975, Q08ER8, Q14588, Q14590, Q32KN0, Q3V080, Q4V8A8, Q5CZA5, Q5R4K8, Q5R5Q6, Q5R9S5, Q5RBX0, Q61751, Q6GQR8, Q6P560, Q6ZMS4, Q7TSH9, Q7TSI0, Q7Z3I7, Q7Z3V5, Q8BLB0, Q8N141, Q8N184, Q8N823, Q8N8J6, Q8N9F8, Q8TBZ5, Q8TF47, Q96ND8

Diamond homologs: A0A1W2PQL4, A6NK75, A6NN14, A6NNF4, A6NP11, A8MQ14, A8MTY0, A8MUV8, A8MXY4, B4DX44, B4DXR9, E9PYI1, O14628, O43345, O75290, O75346, O75373, O75437, O95780, P0CB33, P0DKX0, P0DPD5, P16373, P17019, P17038, P21506, P35789, P52736, P52738, P52744, Q03923, Q03924, Q03936, Q03938, Q05481, Q14586, Q14593, Q14929, Q15928, Q3KNS6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

51 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	44
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
625760	GRCh37/hg19 19q13.11-13.12(chr19:35111811-37744992)	Pathogenic

SpliceAI

698 predictions. Top by Δscore:

Variant	Effect	Δscore
19:36394106:CAAAT:C	acceptor_gain	1.0000
19:36394110:TCTAA:T	acceptor_loss	1.0000
19:36394111:C:CA	acceptor_loss	1.0000
19:36407881:CCTTA:C	donor_loss	1.0000
19:36407884:TACC:T	donor_loss	1.0000
19:36407885:A:AC	donor_gain	1.0000
19:36407885:A:T	donor_loss	1.0000
19:36407885:AC:A	donor_gain	1.0000
19:36407886:C:CA	donor_loss	1.0000
19:36407886:C:CC	donor_gain	1.0000
19:36407886:CC:C	donor_gain	1.0000
19:36408009:GATCG:G	acceptor_gain	1.0000
19:36408011:TCG:T	acceptor_gain	1.0000
19:36408012:CG:C	acceptor_gain	1.0000
19:36408012:CGC:C	acceptor_gain	1.0000
19:36408014:C:CC	acceptor_gain	1.0000
19:36408014:CTG:C	acceptor_loss	1.0000
19:36408015:T:C	acceptor_loss	1.0000
19:36409779:A:AC	donor_gain	1.0000
19:36409780:C:CC	donor_gain	1.0000
19:36394109:AT:A	acceptor_gain	0.9900
19:36394111:C:CC	acceptor_gain	0.9900
19:36405574:CCTCA:C	donor_loss	0.9900
19:36405575:CTCAC:C	donor_loss	0.9900
19:36405576:TCAC:T	donor_loss	0.9900
19:36405577:CAC:C	donor_loss	0.9900
19:36405578:A:T	donor_loss	0.9900
19:36405579:C:CT	donor_loss	0.9900
19:36405596:T:TA	donor_gain	0.9900
19:36405601:T:A	donor_gain	0.9900

AlphaMissense

3541 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:36392879:A:C	F487L	0.996
19:36392879:A:T	F487L	0.996
19:36392881:A:G	F487L	0.996
19:36393551:A:C	F263L	0.996
19:36393551:A:T	F263L	0.996
19:36393553:A:G	F263L	0.996
19:36392795:A:C	F515L	0.995
19:36392795:A:T	F515L	0.995
19:36392797:A:G	F515L	0.995
19:36393131:A:C	F403L	0.995
19:36393131:A:T	F403L	0.995
19:36393133:A:G	F403L	0.995
19:36392963:A:C	F459L	0.994
19:36392963:A:T	F459L	0.994
19:36392965:A:G	F459L	0.994
19:36393047:G:C	F431L	0.994
19:36393047:G:T	F431L	0.994
19:36393049:A:G	F431L	0.994
19:36393299:A:C	F347L	0.994
19:36393299:A:T	F347L	0.994
19:36393301:A:G	F347L	0.994
19:36392852:A:C	H496Q	0.993
19:36392852:A:T	H496Q	0.993
19:36393215:A:C	F375L	0.992
19:36393215:A:T	F375L	0.992
19:36393217:A:G	F375L	0.992
19:36393282:A:G	L353P	0.992
19:36393114:A:G	L409P	0.991
19:36393534:A:G	L269P	0.991
19:36393803:G:C	F179L	0.991

dbSNP variants (sampled 300 via entrez): RS1000254256 (19:36413349 T>C), RS1000293510 (19:36407731 G>A), RS1000368278 (19:36388346 G>C), RS1000423882 (19:36388146 C>G), RS1000442924 (19:36417522 A>G), RS1000602554 (19:36401595 C>A,T), RS1000674979 (19:36387064 G>A), RS1000760220 (19:36386297 A>G), RS1000778927 (19:36394823 C>G), RS1000873267 (19:36410741 T>C), RS1000903478 (19:36400048 G>A,C), RS1000914589 (19:36401867 G>T), RS1000946742 (19:36394392 T>A,C), RS1001253004 (19:36418536 A>G), RS1001297864 (19:36406601 T>C)

Disease associations

OMIM: gene `` | disease phenotypes: MIM:604233

GenCC curated gene-disease

Mondo (1): generalized epilepsy with febrile seizures plus, type 1 (MONDO:0011416)

Orphanet (1): Genetic epilepsy with febrile seizure plus (Orphanet:36387)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST007429_91	Lung function (FVC)	4.000000e-09

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004312	vital capacity

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C565809	Generalized Epilepsy With Febrile Seizures Plus, Type 1 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression	4
arsenite	affects binding, decreases reaction, increases methylation	2
Benzo(a)pyrene	affects methylation, decreases methylation, increases expression, increases methylation	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
TAK-243	increases sumoylation	1
urushiol	decreases expression	1
triphenyl phosphate	affects expression	1
uranyl acetate	affects expression	1
propionaldehyde	increases expression	1
terbufos	increases methylation	1
sodium arsenite	decreases expression	1
butyraldehyde	increases expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Temozolomide	increases expression	1
Atrazine	decreases expression	1
Doxorubicin	decreases expression	1
Fonofos	increases methylation	1
Formaldehyde	decreases expression	1
Parathion	increases methylation	1
Plant Extracts	affects cotreatment, increases expression	1
Uranium	affects expression	1
Aflatoxin B1	increases methylation	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.